Product Description
AN-1792 was the first active immunotherapy strategy forÊAlzheimer's disease. AN-1792 consists of synthetic full-length A_Êpeptide with QS-21 adjuvant. The rationale was that AN-1792 would induce an immune response that would remove brain amyloid deposition. Extensive preclinical evidence showed that immunization with A_1-42 peptide can prevent or reverse the development of the neuropathological hallmarks of Alzheimer's disease, including amyloid plaque formation, neuritic dystrophy, synaptic loss, gliosis, and impaired performance in behavioral assays (Sourced from: https://www.alzforum.org/therapeutics/an-1792)
Mechanisms of Action: Vaccine,AB
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Alzheimer Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| AN-1792-201 | P2 |
Terminated |
Alzheimer Disease |
None |
2019-03-21 |